CD274 and non-small cell lung carcinoma: In advanced-stage NSCLC, first-line anti-PD-1/PD-L1 monotherapy is favored for the patients with ≥ 50% pre-treatment PD-L1 expression.18–21 However studies on early neoadjuvant therapies have shown controversy on predictive values of PD-L1 expression.